Hosted in Boston in collaboration with the British Consulate, this event highlights groundbreaking strategies and partnerships accelerating healthcare advancements. Our team will discuss initiatives focusing on innovative treatment pathways and technological breakthroughs. From AI-driven diagnostics to next-generation therapies, the topics are designed to inspire transformative collaborations. Reach out to schedule a discussion with us and explore how our expertise aligns with your goals in innovation.
Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD
November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
